Nucleic acid therapeutics

Assessing Immune Reaction Risks of Genetic Medicines: Detailed Evaluation of ASO, siRNA, and Non-Vaccine mRNA Lipid Nanoparticle Therapies

Updated

Abstract

Nucleic acid therapies can trigger immune responses that may affect treatment efficacy and safety.

  • Nucleic acid therapeutics, such as antisense oligonucleotides and small interfering RNAs, are emerging as important tools in precision medicine.
  • These therapies can provoke unwanted immune reactions, which could negatively impact their effectiveness.
  • A comprehensive immunogenicity risk assessment framework is proposed to tailor clinical testing strategies based on the immunogenic potential of different nucleic acid modalities.
  • Recommendations include minimal monitoring for therapies with low immunogenic impact and extensive testing for those with safety concerns.
  • The proposed strategies aim to facilitate the development of safe and effective nucleic acid-based therapies.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free